The promising research findings for patients with spinal cord injury (SCI) introduced in an international journal are drawing a big attention from the academic community.
Pharmicell(005690) unveiled its findings on 29th that studies on the effects of Cellgram-SCI, stem cell therapeutics, to treat patients with spinal cord injury suggest that multiple dosing is much more effective than single dose use.
Prof. Jeon Sang Yong of Seoul Asan Medical Center and his team have been using ‘Cellgram-SCI produced by Pharmicell to treat paralyzed patients on clinical trials and revealed their findings on the latest edition of the Journal of ‘Neurosurgery’, the official journal of the AANS (American Association of Neurological Surgeons).
This is the second time that Jeon and his team presented treatment effects proven by clinical research using ‘Cellgram-SCI’ in the journal since 2012. In the previous clinical study, the Cellgram was injected into patients’ body three times but this time only one single dose was applied.
“Two rounds of clinical trials indicate that multiple dosing is way better than single dosing to improve the conditions of tetraplegia patients damaged by chronic spinal cord injury in the kinematic and neurological context,” said Jeon
He more added, “Yet, MRI/DTI test results of some patients with improved conditions despite single dose of stem cell therapy injection show fiber continuity on the injured parts their spinal cord which was non-existent before the treatment, and that implies neural regeneration led by the stem cell therapy.”
“Since regenerative ability of nerve cells is limited, stem cell-based therapies are desperately needed,” said Kim, Hyeon-Soo, head of Pharmicell. “These encouraging results from the trial will give a hope to patients suffering from incurable diseases including paralyzed patients damaged by spinal cord injury.”